SCHEMBL433105

SCHEMBL433105

COC(=O)CCc1ccc(OCc2cccc(/C(=N/OCCN(C)C)c3ccccc3)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESRRB O95718 1/20 0.46
FFAR1 O14842 9/20 0.45
EGFR P00533 2/20 0.45
FFAR4 Q5NUL3 4/20 0.44
AKR1B1 P15121 1/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
PKM P14618 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
MRGPRX4 Q96LA9 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
LTA4H P09960 1/20 0.43
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15248881 1.00 ESRRB (0.46) ESRRBFFAR1EGFRFFAR4AKR1B1
SCHEMBL433106 1.00 ESRRB (0.46) ESRRBFFAR1EGFRFFAR4AKR1B1
SCHEMBL10267026 0.92 FFAR1 (0.55) FFAR1FFAR4AKR1B1
SCHEMBL15239414 0.92 FFAR1 (0.55) FFAR1FFAR4AKR1B1
SCHEMBL15239412 0.92 FFAR1 (0.55) FFAR1FFAR4AKR1B1
SCHEMBL15239169 0.83 FFAR1 (0.53) FFAR1FFAR4AKR1B1RAB9ASMN1; SMN2
SCHEMBL15239494 0.83 FFAR1 (0.53) FFAR1FFAR4AKR1B1RAB9ASMN1; SMN2
SCHEMBL433987 0.83 FFAR1 (0.53) FFAR1FFAR4AKR1B1RAB9ASMN1; SMN2
SCHEMBL435228 0.79 FFAR1 (0.57) FFAR1FFAR4AKR1B1RAB9ASMN1; SMN2
SCHEMBL10259784 0.79 FFAR1 (0.61) FFAR1FFAR4AKR1B1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
EP-2595952-A1 AGONISTS OF GPR40 Connexios Life Sciences Pvt. Ltd. (IN) 2013-05-29 EP disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 ESRRB 145/4885FFAR1 24/4885EGFR 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.